Provided by Tiger Fintech (Singapore) Pte. Ltd.

AC Immune SA

2.04
+0.310017.92%
Post-market: 2.050.0088+0.43%17:40 EDT
Volume:428.87K
Turnover:835.85K
Market Cap:201.84M
PE:-3.46
High:2.09
Open:1.74
Low:1.74
Close:1.73
Loading ...

AC Immune SA Announces Board Changes Ahead of June 2025 AGM

TIPRANKS
·
19 May

AC Immune Sa: Martin ZÜGel Md Will Be Proposed as New Board Chair

THOMSON REUTERS
·
19 May

AC Immune Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
01 May

AC Immune Sa : H.c. Wainwright Cuts Target Price to $12 From $16

THOMSON REUTERS
·
01 May

AC Immune Q1 EPS $(0.21) Misses $(0.20) Estimate, Sales $1.10M Beat $300.67K Estimate

Benzinga
·
30 Apr

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

Zacks
·
30 Apr

BRIEF-AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Reuters
·
30 Apr

AC Immune: Q1 Earnings Snapshot

Associated Press Finance
·
30 Apr

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
30 Apr

AC Immune Sa: Cash Resources of CHF 145.7 Mln as of March 31 Provides Funding Into Q1 2027

THOMSON REUTERS
·
30 Apr

AC Immune Q1 EPS CHF -0.19

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Operating Expenses CHF -20.36 Million

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Pretax Profit CHF -19.029 Million

THOMSON REUTERS
·
30 Apr

AC Immune Q1 Operating Income CHF -19.37 Million

THOMSON REUTERS
·
30 Apr

Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week

Simply Wall St.
·
26 Apr

AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

BRIEF-AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date

Reuters
·
02 Apr

AC Immune Sa - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported to Date

THOMSON REUTERS
·
02 Apr

AC Immune Reports Further Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

THOMSON REUTERS
·
02 Apr

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

GlobeNewswire
·
02 Apr